Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression

Tu1913 Differential Regulation of Oxidative Stress and Apoptosis Related Genes During Active and Inactive Crohn's Disease (CD)

(2015) Marisa Iborra et al.   GASTROENTEROLOGY

The Anti-Apoptotic Bcl-2 Family Member Mcl-1 Promotes T Lymphocyte Survival at Multiple Stages

(2014) I. Dzhagalov et al.   JOURNAL OF IMMUNOLOGY

Impaired removal of Vβ8+lymphocytes aggravates colitis in mice deficient for B cell lymphoma-2-interacting mediator of cell death (Bim)

(2013) K. Leucht et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

(2012) Axel Dignass et al.   Journal of Crohns & Colitis

Antibodies Against Tumor Necrosis Factor (TNF) Induce T-Cell Apoptosis in Patients With Inflammatory Bowel Diseases via TNF Receptor 2 and Intestinal CD14+ Macrophages

(2011) Raja Atreya et al.   GASTROENTEROLOGY

Apoptosis of regulatory T lymphocytes is increased in chronic inflammatory bowel disease and reversed by anti-TNF  treatment

(2011) C. Veltkamp et al.   GUT

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

The BH3-mimetic ABT-737 inhibits allogeneic immune responses

(2011) Pietro E. Cippà et al.   TRANSPLANT INTERNATIONAL

Increased proportion of CD16+ NK cells in the colonic lamina propria of inflammatory bowel disease patients, but not after azathioprine treatment

(2010) A. W. Steel et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells

(2010) O Kutuk et al.   CELL DEATH AND DIFFERENTIATION

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management

(2010) A. Dignass et al.   Journal of Crohns & Colitis

Bcl-2-regulated cell death signalling in the prevention of autoimmunity

(2010) D Tischner et al.   Cell Death & Disease

The Bcl-2 Family Antagonist ABT-737 Significantly Inhibits Multiple Animal Models of Autoimmunity

(2009) P. D. Bardwell et al.   JOURNAL OF IMMUNOLOGY

Bim Upregulation by Histone Deacetylase Inhibitors Mediates Interactions with the Bcl-2 Antagonist ABT-737: Evidence for Distinct Roles for Bcl-2, Bcl-xL, and Mcl-1

(2009) S. Chen et al.   MOLECULAR AND CELLULAR BIOLOGY

The Bcl-2 Homology Domain 3 Mimetic ABT-737 Targets the Apoptotic Machinery in Acute Lymphoblastic Leukemia Resulting in Synergistic in Vitro and in Vivo Interactions with Established Drugs

(2009) L. M. High et al.   MOLECULAR PHARMACOLOGY

Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models

(2008) A. R. Shoemaker et al.   CLINICAL CANCER RESEARCH

Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines

(2008) S Ben-Horin et al.   GUT